Literature DB >> 7921922

Growth factors and hematopoietic recovery.

S C Gulati1, R Gopal, J B Prowda, S Spanik, M Jain, A Gopal.   

Abstract

Availability of hematopoietic growth factors (GC-SF, GM-CSF, erythropoietin, etc.) has started a new arena of dose-intensification. The use of such growth factors has resulted in faster hematopoietic recovery of cancer patients and now offers several new treatment modifications. These include: (1)dose-intensification without hematopoietic stem cell support, (2) speedier hematopoietic recovery after hematoablative therapy and stem cell transplantation (allogeneic or autologous); (3) use of combination of growth factors, and (4) improvement in the delivery of anti-microbial drugs which are toxic towards hematopoietic cells (Gancyclovir, Bactrim, etc.). The above treatment strategies are under active clinical trials and can provide improved, cost-effective methods of treating patients with cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7921922     DOI: 10.1007/bf02990084

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  43 in total

Review 1.  Defining a therapeutic dose of peripheral blood stem cells.

Authors:  J G Bender; L B To; S Williams; L S Schwartzberg
Journal:  J Hematother       Date:  1992

Review 2.  Does stem cell exhaustion result from combining hematopoietic growth factors with chemotherapy? If so, how do we prevent it?

Authors:  M A Moore
Journal:  Blood       Date:  1992-07-01       Impact factor: 22.113

Review 3.  Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1).

Authors:  G J Lieschke; A W Burgess
Journal:  N Engl J Med       Date:  1992-07-02       Impact factor: 91.245

4.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease.

Authors:  S C Gulati; C L Bennett
Journal:  Ann Intern Med       Date:  1992-02-01       Impact factor: 25.391

5.  Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy.

Authors:  G Morstyn; L Campbell; G Lieschke; J E Layton; D Maher; M O'Connor; M Green; W Sheridan; M Vincent; K Alton
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

6.  Did we focus on the most important issues in the use of growth factors and stem-cell transplantation?

Authors:  S C Gulati
Journal:  J Clin Oncol       Date:  1994-04       Impact factor: 44.544

7.  Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients.

Authors:  S Siena; M Bregni; B Brando; N Belli; F Ravagnani; L Gandola; A C Stern; P M Lansdorp; G Bonadonna; A M Gianni
Journal:  Blood       Date:  1991-01-15       Impact factor: 22.113

8.  Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors.

Authors:  W Brugger; K J Bross; M Glatt; F Weber; R Mertelsmann; L Kanz
Journal:  Blood       Date:  1994-02-01       Impact factor: 22.113

9.  Gene-marking to trace origin of relapse after autologous bone-marrow transplantation.

Authors:  M K Brenner; D R Rill; R C Moen; R A Krance; J Mirro; W F Anderson; J N Ihle
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

10.  Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia.

Authors:  C B Miller; L C Platanias; S R Mills; M L Zahurak; M J Ratain; D S Ettinger; R J Jones
Journal:  J Natl Cancer Inst       Date:  1992-01-15       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.